11:42 AM EDT, 06/17/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) rose more than 16% in Monday trading after reporting positive interim results for its volixibat drug candidate during phase 2b testing in patients experiencing inflammation of their bile duct systems.

According to the company, patients with either primary biliary or sclerosing cholangitis who were treated with the oral ileal bile acid transporter showed a statistically significant improvement in their pruritus (itchy skin) symptoms compared with patients treated with a placebo.

The interim results also showed that 75% of the volixibat patients saw a more than 50% reduction in their serum bile acids as well as significantly less fatigue at week 16 compared to patients in the placebo group. Researchers did not see any new safety signals during the mid-stage study, with most adverse events relatively mild and similar in both the 20- and 80-milligram treatment groups.

Based on the results, Mirum said it would continue testing volixibat, with study participants receiving 20-milligram doses twice daily.

Price: 30.14, Change: +4.22, Percent Change: +16.28